334 related articles for article (PubMed ID: 31527760)
1. Oral medications for central serous chorioretinopathy: a literature review.
Fusi-Rubiano W; Saedon H; Patel V; Yang YC
Eye (Lond); 2020 May; 34(5):809-824. PubMed ID: 31527760
[TBL] [Abstract][Full Text] [Related]
2. Mineralocorticoid antagonists in the treatment of central serous chorioetinopathy: Review of the pre-clinical and clinical evidence.
Bousquet E; Zhao M; Daruich A; Behar-Cohen F
Exp Eye Res; 2019 Oct; 187():107754. PubMed ID: 31401003
[TBL] [Abstract][Full Text] [Related]
3. Mineralocorticoid Receptor Antagonists in Central Serous Chorioretinopathy: A Meta-Analysis of Randomized Controlled Trials.
Wang SK; Sun P; Tandias RM; Seto BK; Arroyo JG
Ophthalmol Retina; 2019 Feb; 3(2):154-160. PubMed ID: 31014765
[TBL] [Abstract][Full Text] [Related]
4. Current Therapeutic Approaches to Chronic Central Serous Chorioretinopathy.
Gülkaş S; Şahin Ö
Turk J Ophthalmol; 2019 Feb; 49(1):30-39. PubMed ID: 30829023
[TBL] [Abstract][Full Text] [Related]
5. Interventions for central serous chorioretinopathy: a network meta-analysis.
Salehi M; Wenick AS; Law HA; Evans JR; Gehlbach P
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011841. PubMed ID: 26691378
[TBL] [Abstract][Full Text] [Related]
6. Systemic Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy.
Yang D; Eliott D
Semin Ophthalmol; 2017; 32(1):36-42. PubMed ID: 27929707
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of eplerenone versus placebo for central serous chorioretinopathy: study protocol for the VICI randomised controlled trial.
Willcox A; Culliford L; Ellis L; Rogers CA; Cree A; Chakravarthy U; Ennis S; Behar-Cohen F; Reeves BC; Sivaprasad S; Lotery A
Eye (Lond); 2019 Feb; 33(2):295-303. PubMed ID: 30194380
[TBL] [Abstract][Full Text] [Related]
8. Minoxidil induced central serous Chorioretinopathy treated with oral Eplerenone - a case report.
Venkatesh R; Pereira A; Jain K; Yadav NK
BMC Ophthalmol; 2020 Jun; 20(1):219. PubMed ID: 32503484
[TBL] [Abstract][Full Text] [Related]
9. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial.
Lotery A; Sivaprasad S; O'Connell A; Harris RA; Culliford L; Ellis L; Cree A; Madhusudhan S; Behar-Cohen F; Chakravarthy U; Peto T; Rogers CA; Reeves BC;
Lancet; 2020 Jan; 395(10220):294-303. PubMed ID: 31982075
[TBL] [Abstract][Full Text] [Related]
10. Eplerenone repurposing in management of chorioretinopathy: Mechanism, nanomedicine-based delivery applications and future trends.
Abdelhakeem E; El-Nabarawi M; Shamma R
Br J Clin Pharmacol; 2022 Jun; 88(6):2665-2672. PubMed ID: 34983084
[TBL] [Abstract][Full Text] [Related]
11. Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy.
Pichi F; Carrai P; Ciardella A; Behar-Cohen F; Nucci P;
Int Ophthalmol; 2017 Oct; 37(5):1115-1125. PubMed ID: 27757733
[TBL] [Abstract][Full Text] [Related]
12. Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy: A Comparative Analysis.
Kapoor KG; Wagner AL
Ophthalmic Res; 2016; 56(1):17-22. PubMed ID: 26982318
[TBL] [Abstract][Full Text] [Related]
13. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy.
Zhao M; Célérier I; Bousquet E; Jeanny JC; Jonet L; Savoldelli M; Offret O; Curan A; Farman N; Jaisser F; Behar-Cohen F
J Clin Invest; 2012 Jul; 122(7):2672-9. PubMed ID: 22684104
[TBL] [Abstract][Full Text] [Related]
14. A new treatment approach - Eplerenone - in central serous chorioretinopathy - Case report.
Cioboata M; Alexandrescu C; Hopinca CA; Pienaru MC; Merticariu A; Schmitzer S
J Med Life; 2016; 9(1):92-94. PubMed ID: 27713772
[TBL] [Abstract][Full Text] [Related]
15. [Eplerenone treatment in chronic central serous chorioretinopathy].
Sampo M; Soler V; Gascon P; Ho Wang Yin G; Hoffart L; Denis D; Matonti F
J Fr Ophtalmol; 2016 Jun; 39(6):535-42. PubMed ID: 27230892
[TBL] [Abstract][Full Text] [Related]
16. The Effect of Eplerenone in Chronic Central Serous Chorioretinopathy Refractory to Photodynamic Therapy.
Karagiannis D; Parikakis E; Kontomichos L; Batsos G; Chatziralli I
Semin Ophthalmol; 2019; 34(6):436-441. PubMed ID: 31309849
[No Abstract] [Full Text] [Related]
17. Randomized controlled trials in central serous chorioretinopathy: A review.
Singh SR; Goté JT; Chhablani J
Eye (Lond); 2023 Nov; 37(16):3306-3312. PubMed ID: 36997794
[TBL] [Abstract][Full Text] [Related]
18. Eplerenone for the treatment of chronic central serous chorioretinopathy: 3-year clinical experience.
Petkovsek DS; Cherfan DG; Conti FF; Hom GL; Ehlers JP; Babiuch AS; Rachitskaya AV; Kaiser PK; Schachat AP; Srivastava SK; Sharma S; Singh RP
Br J Ophthalmol; 2020 Feb; 104(2):182-187. PubMed ID: 31079056
[TBL] [Abstract][Full Text] [Related]
19. Oral Mineralocorticoid-Receptor Antagonists: Choroidal Parameters Changes Using OCT in Central Serous Chorioretinopathy.
Faghihi H; Mohammadzadeh V; Nabavi A; Faghihi S; Kadivar S; Ghassemi F
Ophthalmic Surg Lasers Imaging Retina; 2019 Nov; 50(11):726-733. PubMed ID: 31755972
[TBL] [Abstract][Full Text] [Related]
20. Current Pharmacological Treatment Options for Central Serous Chorioretinopathy: A Review.
Nicolò M; Desideri LF; Vagge A; Traverso CE
Pharmaceuticals (Basel); 2020 Sep; 13(10):. PubMed ID: 32977380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
